The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | BCMA-targeted CAR-T therapy is tolerable in multiple myeloma with CNS involvement
Mahmoud Gaballa, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a study on the safety of BCMA-directed CAR-T therapy in patients with multiple myeloma (MM) with central nervous system (CNS) involvement. The study evaluated idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) and found no excess safety concerns, suggesting that this therapy is tolerable for this patient population. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
